Gilteritinib is a potent FLT3 inhibitor that is FDA-approved for the treatment of relapsed/refractory FLT3-mutated AML based on increased response rates and improved survival compared with chemotherapy alone observed in the randomized phase III ADMIRAL study [44]. Here, FLT3 is linked to acute myeloid leukemia.